We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Up-regulated microRNA-299 corrected with poor prognosis of glioblastoma multiforme patients by targeting ELL2.
- Authors
Qian Huang; Xin-Wen Zhang; Yu-Shui Ma; Gai-Xia Lu; Ru-Ting Xie; Hui-Qiong Yang; Zhong-Wei Lv; Xiao-Ming Zhong; Tao Liu; Shi-Xiong Huang; Da Fu; Chun Xie
- Abstract
Background: An increasing understanding of the genes and molecular pathways of glioblastoma multiforme (GBM) can provide us a useful insight for the development of more effective targeted therapeutic. Methods: To investigate the expression and clinical significance of miR-299 and its target genes in GBM, the expression levels of miR-299 and its target gene in human normal brain tissues and GBM were analyzed in silico using genes microarray and hierarchical clustering analysis followed by validation with quantitative RT-PCR. Results: Our results show that miR-299 is up-regulated in GBM patients. Moreover, patients with low miR-299 expression had longer overall survival (OS) compared with those with high miR-299 expression. RNA polymerase II elongation factor, ELL2, was identified as a miR-299 direct target. High expression of ELL2 together with miR-299 down-regulation correlated with a shorter median OS. Conclusions: Our results provide the first evidence that ELL2 is a direct target of miR-299 and increased ELL2 expression and down-regulation of miR-299 are associated with GBM progression and poor prognosis in patients, suggesting that ELL2 and miR-299 might have potential prognostic value and be used as tumor biomarkers for the diagnosis of patients with GBM.
- Publication
Japanese Journal of Clinical Oncology, 2017, Vol 47, Issue 7, p590
- ISSN
0368-2811
- Publication type
Article
- DOI
10.1093/jjco/hyw188